The record
| Class | metabolic |
|---|---|
| Also known as | Anti-Obesity Drug 9604, hGH Fragment 177-191 modified, Tyr-hGH frag 176-191, AOD9604 |
| Chain length | - |
| Molecular weight | 1,815.1 Da |
| Half-life | ~4 minutes (serum); 2-3 hours (biological effect) |
| Route | SC (research); oral bioavailable |
| Studied for | Obesity/weight management (investigational); Fat loss without muscle loss |
| Research use | Anti-obesity drug development; Lipid metabolism studies; Adipocyte differentiation research |
| What has been shown | Stimulates lipolysis in adipose tissue; Reduces body fat without affecting lean mass; No effect on IGF-1, blood glucose, or growth; May support cartilage health |
| How it works | Mimics the lipolytic (fat-burning) C-terminal fragment of human growth hormone. Upregulates beta-3 adrenergic receptors in adipose tissue, enhancing lipolysis. Activates AMPK pathways. Inhibits lipogenesis without affecting IGF-1 or glucose. |
| Patent status | Development discontinued |
| Regulatory status | Not approved; banned by WADA |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Fat Loss Signaling Environment (affection, 51%)
- Cognitive support (illness, 30%)
- Fat loss without muscle loss (illness, 100%)
- HIV-associated lipodystrophy (illness, 30%)
- Obesity/weight loss (illness, 30%)
- Obesity/weight management (illness, 100%)
- Prostate cancer (illness, 30%)
- Visceral adiposity reduction (illness, 30%)
- Weight gain or constant hunger (symptom, 50%)